Vascularized retinal pigment epithelial detachment in age-related macular degeneration: treatment and RPE tear incidence
- 21 February 2012
- journal article
- retinal disorders
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 250 (9) , 1283-1292
Abstract
Background To review vascularized-pigment epithelial detachment (V-PED) treatment visual outcome, and to assess acute retinal pigment epithelium (RPE) tear incidence. Methods One hundred and thirty-two eyes of 125 consecutive patients with age-related macular degeneration and V-PED were included. Ninety-four eyes (71.2%) were associated with choroidal new vessels (CNV), 38 (28.8%) with retinal angiomatous proliferation (RAP). Patients, treated over a 10-year period with the time-current therapy, received: verteporfin photodynamic therapy (PDT) (group 1, 38 eyes), combined intravitreal triamcinolone acetonide (IVTA) and PDT (group 2, 44 eyes) or intravitreal anti-VEGF injection (bevacizumab or ranibizumab) (group 3, 50 eyes). Results Mean follow-up was 20.5 months. At month 12, all eyes treated with PDT or with IVTA and PDT showed a mean significant severe visual decrease. Eyes with CNV lost −0.67 and −0.37 logMAR (p < 0.01 and p < 0.01 respectively), and eyes with RAP −0.55 and −0.31 logMAR (p < 0.01 and p = 0.01 respectively). RPE tear occurred in 14 eyes (36.8%) and in six eyes (13.6%) in groups 1 and 2 respectively. Eyes treated with anti-VEGF therapy showed slight mean visual acuity decrease at month 12. Those with CNV had a mean baseline best-corrected visual acuity (BCVA) of 0.36 ± 0.24 logMAR, final of 0.44 ± 0.30 logMAR (−0.08 logMAR, n.s.). In eyes with RAP, mean baseline BCVA was 0.58 ± 0.39 logMAR, final was 0.78 ± 0.47 logMAR (−0.20 logMAR, n.s.). RPE tear occurred in 14 eyes (36.8%). Patients with either V-PED with CNV or a better baseline BCVA showed greater risk of acute RPE tear (p = 0.01 and p = 0.003 respectively). Conclusions Effective treatment for vascularized PED is still lacking. Until now, only stabilization of the disease has been achieved using anti-VEGF therapy, but the risk of RPE tear can further hamper our expectations. Baseline characteristics are helpful for prognosis, but patients must be informed of the uncertain response. New therapeutic strategies are needed.Keywords
This publication has 38 references indexed in Scilit:
- One-year outcome after intravitreal ranibizumab for large, serous pigment epithelial detachment secondary to age-related macular degenerationEye, 2011
- Quantification of the Therapeutic Response of Intraretinal, Subretinal, and Subpigment Epithelial Compartments in Exudative AMD during Anti-VEGF TherapyInvestigative Ophthalmology & Visual Science, 2011
- Effect of intravitreal ranibizumab in avascular pigment epithelial detachmentEye, 2009
- Can the risk of retinal pigment epithelium tears after bevacizumab treatment be predicted? An optical coherence tomography studyEye, 2008
- INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR RETINAL ANGIOMATOUS PROLIFERATIONRetina, 2007
- INTRAVITREAL BEVACIZUMAB FOR REFRACTORY PIGMENT EPITHELIAL DETACHMENT WITH OCCULT CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATIONRetina, 2007
- Types of choroidal neovascularisation in newly diagnosed exudative age-related macular degenerationBritish Journal of Ophthalmology, 2007
- PHOTODYNAMIC THERAPY WITH VERTEPORFIN FOR CHOROIDAL NEOVASCULARIZATION ASSOCIATED WITH RETINAL PIGMENT EPITHELIAL DETACHMENT IN AGE-RELATED MACULAR DEGENERATIONRetina, 2007
- Photodynamic therapy for retinal angiomatous proliferations and pigment epithelium detachmentAmerican Journal of Ophthalmology, 2004
- ICGA-GUIDED LASER PHOTOCOAGULATION OF OCCULT CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATIONRetina, 2000